Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0BZCIJ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
JS108
|
|||||
| Synonyms |
DAC 002; DAC- 002; DAC-002; DAC-002/JS108; JS 108; JS-108; JS108; TUB-196; humanized anti-TROP2 mAb-Tub196 conjugate
Click to Show/Hide
|
|||||
| Organization |
Hangzhou DAC Biotech Co., Ltd.; Shanghai Junshi Biosciences Co., Ltd.
|
|||||
| Drug Status |
Phase 1 (Terminated)
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
Undisclosed
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Tumor-associated calcium signal transducer 2 (TROP2)
|
Antigen Info | ||||
| Payload Name |
Tubulysin 196
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
